Nanoparticle- and Microparticle-based Delivery Systems
GPTKB entity
Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Drug Delivery System
|
| gptkbp:advantage |
Enhanced Stability
Improved Bioavailability Reduced Side Effects |
| gptkbp:composedOf |
Nanoparticles
Microparticles |
| gptkbp:deliveredBy |
gptkb:Nucleic_Acids
Vaccines Proteins Peptides Small Molecule Drugs |
| gptkbp:enables |
Crossing Biological Barriers
Protection of Labile Drugs Site-specific Delivery Sustained Release |
| https://www.w3.org/2000/01/rdf-schema#label |
Nanoparticle- and Microparticle-based Delivery Systems
|
| gptkbp:material |
Ceramics
Metals Polymers Proteins Lipids |
| gptkbp:routeOfAdministration |
gptkb:Oral
Intravenous Transdermal Pulmonary Ocular |
| gptkbp:studiedBy |
gptkb:Gene_Therapy
immunotherapy Pain Management Hormone Therapy Tuberculosis Treatment Cardiovascular Diseases Central Nervous System Disorders Autoimmune Diseases Antiviral Therapy Antibiotic Delivery Antifungal Therapy Cancer Therapy Diabetes Treatment HIV Therapy Inflammatory Diseases Ophthalmic Delivery Osteoporosis Treatment Vaccine Delivery |
| gptkbp:usedFor |
Controlled Release
Targeted Drug Delivery |
| gptkbp:usedIn |
gptkb:Biomedicine
Pharmaceuticals |
| gptkbp:bfsParent |
gptkb:David_J._McClements
|
| gptkbp:bfsLayer |
7
|